We claim:
1. A method for increasing high density lipoprotein cholesterol level in a host comprising administering an effective amount of a compound of the formula:
28
wherein:
linker is (CH2)gQ(CH2)h;
g is 1, 2, or 3;
h is 0, 1, 2, or 3;
Q is O, S, or CH2;
X is CH2C(O)OR, C(O)OR, OSO(2 or 3)R4, OPO(2 or 3)R4 or C(O)NR1R2, wherein R, R1, and R2 are independently selected from the group consisting of hydrogen, alkyl, lower alkyl (including methyl), aryl, aralkyl, and alkaryl, all of which may be optionally substituted with one or more independently selected from hydroxy, halo, alkoxy, carboxy and amino; and R4 is H, Na, K, other or other pharmaceutically acceptable monovalent cation wherein R1and R2 may optionally come together to form a 4-8 membered ring;
or its pharmaceutically acceptable salt or prodrug.
2. The method of claim 1, wherein linker is (CH2)gQ(CH2)h;
g is 1 or 2;
h is 0, 1, 2, or 3;
Q is O;
X is C(O)OR; wherein R is independently selected from the group consisting of hydrogen and lower alkyl, which may be optionally substituted with one or more substituent independently selected from hydroxy, halo, alkoxy, carboxy and amino.
3. The method of claim 1, wherein linker is (CH2)gQ(CH2)h;
g is 1 or 2;
h is 0, 1, or 2;
Q is CH2;
X is C(O)OR; R is selected from the group consisting of hydrogen and lower alkyl, which may be optionally substituted with one or more independently selected from hydroxy, halo, alkoxy, carboxy and amino.
4. The method of claim 1, wherein X is C(O)OR.
5. The method of claim 1, wherein X is C(O)OCH3
6. The method of claim 1, wherein X is C(O)OH.
7. The method of embodiment 1 wherein the compound is
29
8. A method to improve the functionality of circulating high density lipoprotein in a host, comprising administering an effective amount of the compound of the formula:
30
wherein:
linker is (CH2)gQ(CH2)h;
g is 1, 2, or 3;
h is 0, 1, 2, or 3;
Q is O, S, or CH2;
X is CH2C(O)OR, C(O)OR, OSO(2 or 3)R4, OPO(2 or 3)R4 or C(O)NR1R2, wherein R, R1, and R2 are independently selected from the group consisting of hydrogen, alkyl, lower alkyl (including methyl), aryl, aralkyl, and alkaryl, all of which may be optionally substituted with one or more independently selected from hydroxy, halo, alkoxy, carboxy and amino; and R4 is H, Na, K, other or other pharmaceutically acceptable monovalent cation;
wherein R1and R2 may optionally come together to form a 4-8 membered ring;
or its pharmaceutically acceptable salt or prodrug.
9. The method of claim 8, wherein linker is CH2)gQ(CH2)h;
g is 1 or 2;
h is 0, 1, 2, or 3;
Q is O;
X is C(O)OR; wherein R is independently selected from the group consisting of hydrogen and lower alkyl, which may be optionally substituted with one or more substituent independently selected from hydroxy, halo, alkoxy, carboxy and amino.
10. The method of claim 8, wherein linker is (CH2)gQ(CH2)h;
g is 1 or 2;
h is 0, 1, or 2;
Q is CH2;
X is C(O)OR; R is selected from the group consisting of hydrogen and lower alkyl, which may be optionally substituted with one or more independently selected from hydroxy, halo, alkoxy, carboxy and amino.
11. The method of claim 8, wherein X is C(O)OR.
12. The method of claim 8, wherein X is C(O)OCH3
13. The method of claim 8, wherein X is C(O)OH.
14. The method of claim 1 or 8, wherein the compound is
31
15. The method of any one of claims 1-14, further comprising administering a compound selected from the group consisting of statins, IBAT inhibitors, MTP inhibitors, cholesterol absorption antagonists, phytosterols, CETP inhibitors, fibric acid derivatives and antihypertensive agents.
16. The method of claim 14, futher comprising the adminstration of the compound ()-(2R,4S)-4-Amino-2-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester or its salts.
17. The method of claim 14, further comprising the administration of a fibric acid derivative selected from the group consisting of clofibrate, fenofibrate, ciprofibrate, bezafibrate and gemfibrozil.
18. A method to increase HDLc that includes administering a compound of formula
32
in combination or alternation with a lipid modulating agent.
19. A method to increase HDLc that includes administering a compound of formula
33
above in combination or alternation with a compound selected from the group consisting of nother a compound selected from the group consisting of statins, IBAT inhibitors, MTP inhibitors, cholesterol absorption antagonists, phytosterols, CETP inhibitors, fibric acid derivatives and antihypertensive agents.
20. The method of claim 19, wherein the compound is a CETP inhibitor.
21. The method of claim 20, wherein the compound is ()-(2R,4S)-4-Amino-2-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester or its salt.
22. The method of claim 19, wherein the compound is a fibric acid derivative selected from the group consisting of clofibrate, fenofibrate, ciprofibrate, bezafibrate and gemfibrozil.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-7. (canceled)
8. A computer program product comprising a computer readable medium having a plurality of instructions stored thereon, which, when executed by a processor, cause the processor to perform operations including:
identifying one or more individuals associated with an opportunity included within a CRM system;
creating an instant message buddy list group associated with the opportunity; and
populating the instant message buddy list group with at least a portion of the one or more individuals.
9. The computer program product of claim 8, further including propagating the instant message buddy list group to at least one of the one or more individuals.
10. The computer program product of claim 9, wherein propagating the instant message buddy list group is based on one or more rules.
11. The computer program product of claim 8, further including:
identifying a change to the one or more individuals associated with the opportunity, and
updating the instant message buddy list group based on the change.
12. The computer program product of claim 11, wherein updating the instant message buddy list group includes removing an individual from the instant message buddy list group.
13. The computer program product of claim 11, wherein updating the instant message buddy list group includes adding an individual to the instant message buddy list group.
14. The computer program product of claim 11, further including propagating the updated instant message buddy list group to at least one of the one or more individuals.
15. A computing system comprising:
one or more processor devices; and
one or more memory architectures coupled with the one or more processor devices;
wherein the one or more processor devices are configured to:
identify one or more individuals associated with an opportunity included within a CRM system;
create an instant message buddy list group associated with the opportunity; and
populate the instant message buddy list group with at least a portion of the one or more individuals.
16. The computer system of claim 15, wherein the one or more processor devices are further configured to:
propagate the instant message buddy list group to at least one of the one or more individuals.
17. The computer system of claim 15, wherein the one or more processor devices are further configured to:
identify a change to the one or more individuals associated with the opportunity, and
update the instant message buddy list group based on the change.
18. The computer system of claim 17, wherein updating the instant message buddy list group includes removing an individual from the instant message buddy list group.
19. The computer system of claim 17, wherein updating the instant message buddy list group includes adding an individual to the instant message buddy list group.
20. The computer system of claim 17, further including propagating the updated instant message buddy list group to at least one of the one or more individuals.